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Abstract
Background: The process of HIV-1 genomic RNA (gRNA) encapsidation is governed by a number of viral encoded
components, most notably the Gag protein and gRNA cis elements in the canonical packaging signal (ψ). Also
implicated in encapsidation are cis determinants in the R, U5, and PBS (primer binding site) from the 5’
untranslated region (UTR). Although conventionally associated with nuclear export of HIV-1 RNA, there is a
burgeoning role for the Rev/RRE in the encapsidation process. Pleiotropic effects exhibited by these cis and trans
viral components may confound the ability to examine their independent, and combined, impact on encapsidation
of RNA into HIV-1 viral particles in their innate viral context. We systematically reconstructed the HIV-1 packaging
system in the context of a heterologous murine leukemia virus (MLV) vector RNA to elucidate a mechanism in
which the Rev/RRE system is central to achieving efficient and specific encapsidation into HIV-1 viral particles.
Results: We show for the first time that the Rev/RRE system can augment RNA encapsidation independent of all
cis elements from the 5’ UTR (R, U5, PBS, and ψ). Incorporation of all the 5’ UTR cis elements did not enhance RNA
encapsidation in the absence of the Rev/RRE system. In fact, we demonstrate that the Rev/RRE system is required
for specific and efficient encapsidation commonly associated with the canonical packaging signal. The mechanism
of Rev/RRE-mediated encapsidation is not a general phenomenon, since the combination of the Rev/RRE system
and 5’ UTR cis elements did not enhance encapsidation into MLV-derived viral particles. Lastly, we show that
heterologous MLV RNAs conform to transduction properties commonly associated with HIV-1 viral particles,
including in vivo transduction of non-dividing cells (i.e. mouse neurons); however, the cDNA forms are episomes
predominantly in the 1-LTR circle form.
Conclusions: Premised on encapsidation of a heterologous RNA into HIV-1 viral particles, our findings define a
functional HIV-1 packaging system as comprising the 5’ UTR cis elements, Gag, and the Rev/RRE system, in which
the Rev/RRE system is required to make the RNA amenable to the ensuing interaction between Gag and the
canonical packaging signal for subsequent encapsidation.
Background
Specific and efficient encapsidation of HIV-1 gRNA into
viral particles is a multifaceted process of relocating the
gRNA following transcription in the nucleus to sites of
particle assembly at the plasma membrane. Cis packaging
signals in the viral RNA confer specific selection among
the milieu of host cell RNAs through interactions with
trans factors encoded by the virus, and host cell. The
conventional canonical cis packaging signal (ψ)i sa~ 1 2 0
bp fragment comprised of four stem-loop structures
located in the HIV-1 5’ untranslated region (UTR), and
extending into the 5’ end of the HIV-1 Gag coding
sequence [1]. Interactions of the Gag polyprotein with
stem-loops 2, 3, and 4 ensure efficient encapsidation of
the gRNA [1]. Nonetheless, a fragment that included the
ψ region did not confer packaging of a heterologous
RNA [2]. This is in contrast to the murine leukemia virus
(MLV) gRNA which contains a defined cis element of
~175 bp in its 5’ UTR capable of packaging heterologous
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indicate that the HIV-1 packaging system is more com-
plex than that of MLV, comprising multiple cis elements,
some of which are outside of the canonical packaging sig-
nal. A number of loss-of-function studies demonstrated
that additional cis elements throughout the 5’ UTR (R,
U5, and PBS) also impact encapsidation of gRNA [5-8].
HIV-1 cis and trans components influence gRNA
encapsidation through RNA-RNA and RNA-protein
interactions occurring within the nucleus and cytoplasm,
prior to localization of Gag-RNA complexes to sites of
particle assembly at the plasma membrane. Cytoplasmic
interactions, such as RNA-RNA dimerization [9] and
Gag-RNA interactions [10], are critical steps in the
encapsidation mechanism, but are downstream steps to
the export of RNA from the nucleus to the cytoplasm.
The HIV-1 Rev protein mediates nuclear export of
unspliced full-length, as well as partially spliced, viral
RNAs by bridging an interaction between the Rev
response element (RRE) in the gRNA and the host cell
CRM1 nuclear export pathway [11]. The Rev/RRE sys-
tem is highly conserved among lentiviruses; a mechan-
ism not shared by simple retroviruses such as MLV,
which accomplish RNA nuclear export independent of
viral encoded proteins [12,13]. Accumulating evidence
indicates that the Rev/RRE system also contributes to
translation and RNA encapsidation events that occur in
the cytoplasm, after nuclear export [14]. HIV-1 Rev was
shown to enhance translation 1-3 orders of magnitude,
concurrent with nominal changes in cytoplasmic RNA
levels [15]. In the context of HIV-1 virus, and viral vec-
tors, the Rev/RRE was also identified to influence RNA
encapsidation into viral particles [16-19]. The HIV-1
Rev protein is not known to be a constituent of the viral
particle, thus, conceivably, Rev may influence gRNA
encapsidation at a step prior to, or coincident with the
Gag-RNA interaction, and consequently incorporation
of the gRNA into a viral particle. As alluded to above,
disparate studies indicate that efficient and specific RNA
encapsidation into HIV-1 viral particles rely upon multi-
ple components comprised of both cis elements in the
RNA (R, U5, PBS, ψ, and RRE) and viral encoded trans
factors (Gag protein and Rev). However, it is not under-
stood if these components can function independently
of each other, or if the RNA encapsidation mechanism
is a single pathway relying upon the concerted effects of
the various components.
We reasoned that the HIV-1 Rev/RRE system and cis
elements in the 5’ UTR may function within the same
pathway, thus the combined effects may be necessary
for efficient and specific encapsidation of RNA into
HIV-1 viral particles. Mutational analysis, in the innate
viral context, has commonly been used to address the
contributions of the abovementioned cis elements and
trans factors to encapsidation [1]; however, difficulty in
parsing pleiotropic functions may confound effects
attributed to encapsidation. A system that relies upon
gain-of-function may be suitable for discerning the
impact of multiple viral components on encapsidation.
Here, the Rev/RRE system and 5’ UTR cis elements
were systematically reconstructed in the middle of a
simple retroviral vector RNA (derived from MLV) to
investigate the collective, and independent, impact on
the gain of encapsidation function into HIV-1 derived
viral particles. We show that i) the Rev/RRE system can
augment encapsidation of MLV vector RNA indepen-
dent of the canonical HIV-1 packaging signal; ii) the
Rev/RRE system is required for cis elements from the 5’
UTR to mediate efficient and specific encapsidation into
HIV-1 viral particles; iii) a functional packaging system
is composed of multiple components (including 5’ UTR
cis elements, nucleocapsid, and Rev/RRE system); iv) the
Rev/RRE system and 5’ UTR cis elements synergize to
increase vector titers that rival those of HIV-1 derived
vectors; and v) HIV-1 delivered heterologous RNAs ren-
der episomes (predominantly 1-LTR circles) in trans-
duced cells that may prove beneficial as non-integrating
vectors in gene therapy protocols.
Results
HIV-1 Rev augments encapsidation of a heterologous
RNA independent of the canonical HIV-1 packaging signal
The Rev/RRE system was recently demonstrated to
enhance encapsidation of a HIV-1 vector RNA into
HIV-1 viral particles [17]. In this previous work, how-
ever, the Rev/RRE system was examined in the context
of HIV-1 vectors that contain cis elements from the 5’
UTR including R, U5, PBS, and ψ regions that may also
have contributed to the enhanced encapsidation. Addi-
tionally, the combination of the Rev/RRE system and cis
elements from the 5’ UTR may have pleiotropic effects
which impact other stages of the viral life cycle (i.e.
reverse transcription [20]). To isolate encapsidation
effects directly attributable to the Rev/RRE system we
assembled a heterologous RNA system derived from
murine leukemia virus (MLV) vector RNA (Figure 1A).
Nuclear export of MLV vector RNA is autonomous
[12,13], a feature exploited to elucidate the effects of the
Rev/RRE on HIV-1 processes (i.e. encapsidation). Het-
erologous vector RNAs were packaged into viral parti-
cles generated from a helper system (Gag/Pol-4X CTE)
that does not rely upon the Rev/RRE system for nuclear
export of RNA encoding the structural and enzymatic
proteins (Figure 1A). By circumventing dependence
upon Rev for nuclear export of gag/pol RNA, and vector
RNA, we could directly analyze the effect of Rev on
encapsidation. The MLV/HIV RRE chimeric vector was
constructed to express enhanced green fluorescent
Cockrell et al. Retrovirology 2011, 8:51
http://www.retrovirology.com/content/8/1/51
Page 2 of 17protein (eGFP) from an internal CMV promoter to pro-
vide an indirect indication of the RNA incorporated into
viral particles (Figure 1A). Vector titers were determined
by scoring for GFP expression following transduction of
293T cells, and normalized to amounts of p24 capsid
protein (Figure 1B). Incorporation of only the HIV-1
RRE into the heterologous MLV vector (MLV/HIV RRE
vector) enhanced titers 11-fold in the presence of Rev.
This is the first report that the Rev/RRE system can
influence packaging of a foreign RNA into HIV-1 viral
particles. These results indicate that the HIV-1 Rev/RRE
system can impact titers of vectors devoid of HIV-1 cis
elements known to affect RNA packaging. Furthermore,
the Rev/RRE system conferred corresponding increases
in transduction of 293T cells exposed to equivalent
amounts of p24 capsid protein (Figure 2A and 2B),
demonstrating that the Rev mediated increase in titer
cannot be attributed to Rev effects on HIV-1 particle
production. Since it is well established that the Rev pro-
tein enhances nuclear export of RNAs containing a
RRE, observed increases in titers may be a consequence
of augmented nuclear export. This possibility was inves-
tigated by measuring the cytoplasmic vector levels in the
producer cells.
The vectors were configured to indirectly assess cyto-
plasmic levels of vector length RNAs during production
by situating the firefly luciferase gene such that it was
included in the full-length vector RNA, but not in
RNAs expressed from the internal promoter (Figure
1A). Luciferase expression in the 293T producer cells is
A
B C
A
D
Figure 1 HIV-1 Rev/RRE system and cis elements in the 5’UTR augment vector titers. A. Full-length MLV/HIV chimeric vector RNAs are
expressed from a CMV (cytomegalovirus) promoter in transfected 293T cells. MLV and HIV cis elements can be distinguished by black
underscore. Chimeric vector names are represented as MLV/HIV followed by corresponding HIV cis elements incorporated: RRE (Rev Response
Element), R (repeat), U5 (unique region 5), PS (packaging signal comprised of ψ [canonical packaging signal and into 5’ Gag region]), cPPT
(central polypurine tract), PBS (primer binding site). Also incorporated are the WPRE (woodchuck hepatitis virus post-transcriptional regulatory
element), FLuc (firefly luciferase gene), and GFP (green fluorescent protein gene). HIV-1 Gag-Pol 4X CTE helper construct was used to express
structural and enzymatic proteins to generate viral particles independent of HIV-1 Rev protein. B. Vector titers normalized to p24 are shown in
the absence (white bars) and presence (black bars) of Rev. The influence of adding HIV-1 cis elements to the MLV vector is indicated by fold
increases in the presence of Rev relative to the standard MLV vector. Fold increases for MLV/HIV RRE + PS (38 fold) and MLV/HIV RRE + RU5 (5
fold) are not indicated on the graph. C. Luciferase levels normalized to total protein are shown for each vector. D. Titers expressed as a ratio to
luciferase are shown as arbitrary units (AU). Fold increases for MLV/HIV RRE + PS (22 fold) and MLV/HIV RRE + RU5 (4 fold) are not indicated on
the graph. Error for all bar graphs is expressed as ±S.D. All experiments were performed in triplicate.
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ject to translational influences. Luciferase levels were
marginally affected by Rev, indicating that Rev did not
influence nuclear export of the MLV/HIV RRE vector
(Figure 1C). Examining the titer/luciferase ratio (Figure
1D) revealed that the effects of the Rev/RRE system pri-
marily alter vector titers (14 fold) with minimal cyto-
plasmic changes. Reasoning that the Rev/RRE system
may mediate packaging of vector RNA into HIV-1 viral
particles, we were encouraged to further explore the
mechanism mediating RNA encapsidation.
Encapsidation efficiency is a measure of RNA packaged
into viral particles relative to the RNA available for
packaging, in the cytoplasm. Vector RNA was isolated
from viral particles in the media of 293T producer cells
and vector producing cells were fractionated to obtain
cytoplasmic RNA. Cytoplasmic separation was routinely
monitored using western blot analysis for the absence of
the nuclear specific protein, nucleolin, from the cyto-
plasm (Additional file 1, Figure S1A). Relative RNA levels
in viral particles and cytoplasm of producer cells were
examined by qRT-PCR and northern blot analysis (Figure
3). In the absence of HIV-1 5’ UTR cis elements Rev
enhanced the levels of MLV/HIV RRE vector RNA in
viral particles 6 fold compared to the MLV vector (Figure
3A), which is in line with what was observed for the titers
(Figure 1B). Compared to the basic MLV vector the Rev/
RRE system did not impact cytoplasmic vector RNA
levels (Figure 3B), thus the increase in RNA encapsida-
tion is similar to that observed in viral particles, 7-fold
(Figure 3C). Northern blot analysis supported the obser-
vation that the Rev/RRE system could augment encapsi-
dation independent of additional HIV-1 5’ UTR cis
elements (Figure 3D). Specificity is also apparent from
northern blot analysis, demonstrating that vector length
RNA species is more efficiently packaged in the presence
of Rev than a smaller RNA species (labeled as GFP gener-
ated from the internal promoter) lacking the RRE cis ele-
ment. Overall, our data demonstrate that the Rev/RRE
system can enhance encapsidation of a heterologous
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Figure 2 Transduction of 293T cells with chimeric MLV/HIV vectors packaged into HIV-1 viral particles. Aa n dB . 293T cells were
transduced with equivalent amounts of p24 capsid protein (50 ng), as determined for each of the indicated chimeric vectors. The influence of
the HIV-1 Rev/RRE system, and 5’ UTR cis elements, on transduction was assessed by fluorescence microscopy (A) and FACscan analysis (B) at 7
days post-transduction. C. 293T cells were transduced in the absence (No RT Inhibitor), or presence (+RT Inhibitor), of the HIV-1 specific non-
nucleoside reverse transcriptase inhibitor, etravirine (100 nM). Transduced cells were assessed by fluorescence microscopy and FACscan analysis.
D. The capacity of the MLV/HIV RRE + RU5PS vector to be stably maintained after 4 cell passages was examined by FACscan analysis. The
percent GFP positive cells are indicated for each FACscan and 293T negative control (NC) cells are shown.
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nical HIV-1 packaging signal, as well as other 5’ UTR cis
elements. These data indicate that the Rev/RRE system
may be a central component of a RNA encapsidation
mechanism that is traditionally associated with cis ele-
ments in the 5’ UTR (R, U5, PBS, and ψ). We examined
the proposition that an encapsidation mechanism is the
concerted effect of all these components.
HIV-1 Rev/RRE system is required for the 5’ UTR cis
elements to mediate efficient RNA encapsidation
We have demonstrated that the Rev/RRE system is a
part of the encapsidation mechanism. However, it is
well established that encapsidation is primarily mediated
through cis elements in the 5’ UTR, predominantly pro-
tein-RNA interactions of the nucleocapsid with ψ [10],
and RNA-RNA dimerization via stem-loop 1 of ψ [9].
The HIV-1 Rev/RRE, as well as the aforementioned pro-
tein-RNA and RNA-RNA interactions may comprise a
bona fide packaging system that may be defined by the
capacity to support efficient and specific encapsidation
of a heterologous RNA into HIV-1 derived viral parti-
cles. To characterize the role of the Rev/RRE in the con-
text of a packaging system that comprises the 5’ UTR cis
elements we generated a series of heterologous MLV/
HIV vectors (Figure 1A). The entire 5’ UTR was either
Cytoplasmic RNA Viral Particle RNA
Rev
MLV MLV
MLV/
HIV RRE
MLV/
HIV RRE
GFP
MLV/HIV RRE
MLV
- + - + - + - +
A B C
DE
Figure 3 HIV-1 Rev/RRE and cis elements in the 5’UTR cooperatively enhance RNA encapsidation into HIV-1 viral particles. A. Vector
RNA was measured by qRT-PCR and expressed in arbitrary units (AU). RNA levels for all graphs are shown in the absence (white bars) and
presence (black bars) of Rev. The influence of adding HIV-1 cis elements to the MLV vector is indicated by fold increases in the presence of Rev
relative to the standard MLV vector. Fold increases in vector RNA for MLV/HIV RU5PS (1.9 fold), MLV/HIV RRE + PS (17 fold) and MLV/HIV RRE +
RU5 (7.7 fold) are not indicated on the graph. B. Cytoplasmic RNA was isolated from vector producer 293T cells at the time of vector harvesting.
Relative RNA levels were obtained and recorded as done for vector RNA in part A. C. Efficiency of encapsidating RNA into HIV-1 viral particles is
expressed as a ratio of vector RNA in viral particles to cytoplasmic RNA available for encapsidation. Relative levels are expressed like vector RNA
in part A. Fold increases for MLV/HIV RU5PS (1.2 fold), MLV/HIV RRE + PS (6.7 fold) and MLV/HIV RRE + RU5 (3.9 fold) are not indicated on the
graph. D. Northern blot analysis of cytoplasmic and vector RNA isolated from MLV and MLV/HIV RRE in the absence (-) and presence (+) of Rev.
Vector length RNA species were detected with a GFP labeled probe, as well as an additional RNA species (labeled GFP) generated from the
internal CMV promoter. E. Northern blot analysis of cytoplasmic and vector RNA isolated from MLV/HIV RU5PS and MLV/HIV RRE + RU5PS in the
absence (-) and presence (+) of Rev. Vector length RNA species were detected with a probe to a region in the 5’ end of the vector, as well as an
additional RNA species (labeled ‘partial vector RNA’). Cytoplasmic and vector RNAs are shown at different exposures of the same blot. Last lane
(far right) is a shorter exposure of adjacent left lane. Error for all bar graphs is expressed as ±S.D. All experiments were performed in triplicate.
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RNA (MLV/HIV RU5PS), or inserted in the context of
the RRE (MLV/HIV RRE + RU5PS). Since cis elements
in the R and U5 regions have also been shown to impact
encapsidation [5-8], the 5’ UTR was also further sepa-
rated into the R/U5 (MLV/HIV RRE + RU5) and ψ
(MLV/HIV RRE + PS) in the context of the RRE (Figure
1A). Each of the vectors was titered on 293T cells by
scoring for GFP positive cells, and normalizing to levels
of p24 capsid protein.
The complete contigent of cis elements from the 5’
UTR (MLV/HIV RU5PS) moderately enhanced titers (12
fold) independent of Rev, whereas in the context of the
RRE (MLV/HIV RRE + RU5PS) Rev dramatically aug-
mented titers (626 fold) compared to the basic MLV
vector (Figure 1B); an effect that was visually, and quan-
titatively, outstanding upon transduction of 293T cells
with equivalent amounts of p24 capsid protein (Figure
2A and 2B). Notably, titers of the MLV/HIV RRE +
RU5PS vector were 1.07 × 10
7 TU/ml, which is in the
10
7-10
8 TU/ml range of those obtained with standard
HIV-1 vectors prior to concentration; a comparison that
was also observed after normalization to p24. These
data indicate that the Rev/RRE system and 5’ UTR cis
elements synergize to achieve the increase in vector
titer. Further separation of the 5’ UTR cis elements into
the canonical packaging signal (MLV/HIV RRE + PS) or
R/U5 (MLV/HIV RRE + RU5) did not achieve levels of
titer similar to the vector containing the entire 5’ UTR
and RRE (Figure 1B), demonstrating the significance of
retaining a fully intact 5’ UTR. Furthermore, to confirm
that GFP titers are a result of reverse transcription of
heterologous MLV vector RNA by the HIV-1 reverse
transcriptase, transduction of 293T cells was assessed by
FACs analysis and fluorescence microscopy following
treatment with the HIV-1 specific non-nucleoside RT
inhibitor, etravirine (Figure 2C). Etravirine specifically
inhibited transduction of the MLV/HIV RRE + RU5PS
vector packaged into HIV-1 viral particles, but did not
inhibit transduction of the same vector packaged into
MLV viral particles (Figure 2C). These data also indicate
that GFP expression is not a consequence of pseudo-
transduction. Although Rev enhanced titers of all the
above mentioned vectors containing the RRE, cytoplas-
mic luciferase levels remained relatively similar, indir-
ectly indicating that increased titers were probably not a
consequence of increased nuclear export of vector RNA
(Figure 1C and 1D). The titers were a clear indication
that a comprehensive HIV-1 packaging system may
comprise the synergistic influences of the Rev/RRE sys-
tem and cis elements from the 5’ UTR, as well as
nucleocapsid protein. Considering this possibility, we
sought to directly characterize the Rev impact on the
encapsidation efficiency of heterologous RNAs,
containing cis elements from the 5’ UTR, into HIV-1
viral particles. Quantitative RT-PCR was employed to
quantify vector RNA in viral particles, and in producer
cells.
Surprisingly, as shown in Figure 3 A and 3C, in con-
trast to the increase in vector titers (Figure 1B), incor-
poration of the 5’ UTR cis elements into the
heterologous MLV vector (MLV/HIV RU5PS) did not
enhance RNA encapsidation in either the absence or
presence of Rev. Most importantly, in the context of the
RRE (MLV/HIV RRE + RU5PS), however, the 5’ UTR
cis elements exhibited a 22 fold increase in heterologous
vector RNA encapsidation into HIV-1 viral particles in
the presence of Rev (Figure 3C). Rev-dependent encapsi-
dation was clearly a consequence of enhanced RNA
packaged into viral particles (Figure 3A), not increases
in cytoplasmic RNA (Figure 3B). Notably, however, the
cytoplasmic levels of RNA may vary between experi-
ments, which may be partially due to transfection varia-
tion (Additional file 1, Figure S1 B-D). Nonetheless,
transfection would not impact encapsidation measure-
ments which are derived from the ratio of vector RNA
in the viral particles relative to vector RNA in the cyto-
plasm. These data demonstrate that the Rev-RRE inter-
action may initially be required to render the RNA
amenable for subsequent steps in the encapsidation
mechanism that conventionally involve cis elements
from the 5’ UTR, such as interaction between nucleo-
capsid and the canonical packaging signal. Moreover,
the enhanced encapsidation effect of the MLV/HIV RRE
+ RU5PS chimeric vector is dependent upon the com-
plete contingent of 5’ UTR cis elements, since dissection
of the 5’ UTR cis elements into the canonical packaging
signal (MLV/HIV RRE + PS) or RU5 (MLV/HIV RRE +
RU5) did not result in corresponding increases in encap-
sidation efficiency, in the presence of Rev, which was
comparable to the MLV/HIV RRE vector (Figure 3C).
The Rev-dependent enhancement of MLV/HIV RRE +
RU5PS vector RNA encapsidation obtained by qRT-PCR
was bolstered by northern blot analysis showing strong
Rev-dependent increase in levels of RNA encapsidated
into HIV-1 viral particles, despite nominal changes in
cytoplasmic vector RNA levels (Figure 3E). Notably,
within the cytoplasmic RNAs our probe detects a domi-
nant smaller species of vector RNA (termed ‘partial vec-
tor RNA’). Although the full-length vector RNA is
present at lower levels in the cytoplasm, the Rev/RRE
system and 5’ UTR cis elements impart the ability of the
full-length vector RNA to out compete the more abun-
dant ‘partial vector RNA’ species for packaging into viral
particles (Figure 3E); demonstrating the specificity that
these components confer upon a RNA for encapsidation.
Overall, our data demonstrate that: i) Rev is required
for efficient encapsidation of a heterologous RNA that is
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interactions through cis elements in the 5’ UTR; ii) cis
elements from the 5’ UTR exhibit effects that can
enhance heterologous vector titer without increasing
RNA encapsidation; and iii) a packaging system compe-
tent for heterologous RNA encapsidation should mini-
mally include the Rev/RRE system and all cis elements
of the 5’ UTR.
The HIV-1 Rev/RRE and 5’ UTR cis elements do not
augment RNA encapsidation into MLV derived viral
particles
Manipulating the HIV-1 packaging system, described
above, to efficiently encapsidate a foreign RNA into
HIV-1 viral particles may be a general biological phe-
nomenon that can be exploited for RNA encapsidation
into non-HIV-1 viral particles. The heterologous MLV
RNA vector system was used to examine if the HIV-1
Rev/RRE and 5’ UTR cis elements can mediate packa-
ging of RNA into MLV viral particles, thereby resulting
in a loss of specificity for HIV-1 viral particles. Reten-
tion of the MLV packaging signal bestows dual func-
tionality onto the MLV/HIV RRE + RU5PS chimeric
vector RNA to also allow for packaging into MLV
derived viral particles. Accordingly, this vector was used
t oe x a m i n ei ft h eH I V - 1R e v / R R Ea n d5 ’ UTR cis ele-
ments alter the encapsidation efficiency into MLV viral
particles. Direct comparison of the chimeric vector to
the basic MLV vector revealed that there was little
impact of the Rev/RRE system on normalized titers or
luciferase levels (Figure 4A and 4B). In fact, transduction
with equivalent units of MLV reverse transcriptase
resulted in a reduced number of transduced cells, com-
pared to the basic MLV vector (Figure 4D and 4E).
Moreover, the titers were slightly lower than those of
the basic MLV vector, resulting in decreased levels after
normalization to luciferase (Figure 4C). In contrast to
HIV-1 viral particles, these data indicated that the HIV-
1 Rev/RRE and 5’ UTR cis elements do not influence
the packaging of RNA into MLV viral particles.
Investigation of the encapsidation efficiency into MLV
viral particles exposed a picture similar to that obtained
with the titer/luciferase assays. There was no effect of the
Rev/RRE and 5’ UTR cis elements on levels of vector
RNA in MLV viral particles, or in the producer cell cyto-
plasm (Figure 5A and 5B). Consequently, these HIV-1
components also had no effect on RNA encapsidation
into MLV viral particles (Figure 5C). These results imply
that the Rev/RRE system and 5’ UTR cis elements confer
specificity onto the heterologous MLV vector RNA for
encapsidation into HIV-1 viral particles, but provide no
advantage for encapsidation into MLV viral particles.
Using a single RNA system with different packaging spe-
cificities, we were able to demonstrate that HIV-1 and
MLV commandeer distinct mechanisms to select vector
RNAs from the milieu of host cell RNAs and promote
RNA encapsidation into nascent viral particles.
Packaging chimeric MLV/HIV vector RNAs into HIV-1 viral
particles reveals unique transduction properties
Depending on the type of viral particle, MLV or HIV-1,
carrying the vector RNA, a different transduction profile
may be anticipated. In the context of MLV viral parti-
cles the chimeric vector was retained after multiple cell
passages to eliminate episomal vector DNA species, as
indicated by FACs analysis of GFP positive cells (Figure
5D). In contrast, GFP positive cells from transduction
with HIV-1 delivered chimeric vector were almost com-
pletely eliminated (Figure 2B and 2D), indicating that
GFP may be expressed from episomal DNA vector
forms not competent for integration. The presence of
total episomal DNA forms was assessed by qPCR for
vector copy number (Figure 6A) relative to copy number
of b-globin (Figure 6B). In line with GFP results, qPCR
quantitation of total vector DNA before and after passa-
ging cells yielded a >30 fold decrease in vector DNA
after passaging 293T cells transduced with HIV-1 parti-
cles, compared to <2 fold decrease from MLV viral par-
ticles (Figure 6 C). MLV/HIV chimeric vector RNA
delivered by HIV-1 viral particles primarily cedes pro-
viral episomal DNA forms that can be composed of 1-
LTR, 2-LTR, linear, or mutant forms.
Southern blot analysis revealed that the HIV-1 pack-
aged MLV/HIV RRE + RU5PS vector exists predomi-
nantly as a 1-LTR episome that can be diluted following
multiple cell passages (Figure 6D). In contrast, the same
vector delivered with MLV viral particles exhibited a
very different profile, primarily as integrated DNA
accompanied by minimally detectable levels of linear, 1-
LTR, and 2-LTR episomes (Figure 6D). Reverse tran-
scription of the chimeric vector RNA by HIV-1 RT
clearly leads to dominant 1-LTR episomal species that
are apparently responsible for the observed GFP expres-
sion, albeit expression is extremely low. The chimeric
vector packaged into HIV-1 viral particles curtails the
presence of linear episomal forms that may be substrates
for illegitimate integration as described earlier by Kantor
et al. [21], as well as nonhomologous integration at sites
of strand breakage in the host cell genome. A non-inte-
grating vector that minimizes perturbations of the host
cell genome would be most desirable for gene therapy
protocols.
Unique to lentiviral vectors is the ability to establish
stable transgene expression in non-dividing cells. HIV-1
mediated delivery of a MLV/HIV RRE chimeric vector
that expresses GFP (Figure 7A) demonstrated efficient
transduction of mouse brain neurons in the striatum
(Figure 7B and 7C). HIV-1 delivered vector (GFP
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nucleus (NeuN) marker, whereas the same vector deliv-
ered with MLV viral particles did not exhibit neuronal
transduction (Figure 7B); an observation that was con-
sistent over multiple brain sections (Figure 7C). None-
theless, MLV delivered vector did yield a moderate
number of GFP positive cells that were not NeuN posi-
tive and appeared to be morphologically distinct. These
data are a clear indication that heterologous MLV vector
RNAs, packaged into HIV-1 viral particles, can assume
transduction properties dictated by HIV-1 structural and
enzymatic proteins, with the exception that reverse tran-
scribed cDNAs are not competent for HIV-1 mediated
stable integration.
Discussion
The objective of this study was to understand the role of
the HIV-1 Rev/RRE system in the sophisticated mechan-
ism of selecting a RNA species from the milieu of host
cell RNAs for efficient and specific encapsidation into
HIV-1 viral particles. Rev/RRE-dependent encapsidation
was specifically assessed through reconstruction of the
HIV-1 packaging system in the context of a heterolo-
gous MLV vector RNA, thereby averting the RNA
nuclear export effects of the Rev/RRE system. We have
shown for the first time that the Rev/RRE system can
enhance RNA encapsidation of a heterologous RNA into
HIV-1 viral particles in the absence of more conven-
tional cis packaging elements localized in the 5’ UTR of
AB C
-Rev
+Rev
MLV
MLV/HIV RRE 
+RU5PS
D E
Figure 4 HIV-1 Rev/RRE and cis elements in the 5’UTR do not influence vector titers after packaging into MLV viral particles. A.T i t e r s
of MLV/HIV chimeric vectors were obtained by scoring for GFP positive cells following transduction of 293T cells. Titers are expressed as
transducing units (TU) normalized to the amount of RT units (counts per minute [CPM]). B. Normalized luciferase levels were determined in
transfected 293T producer cells. Luciferase levels were normalized to total cell protein. C. Titers (part A) expressed as a ratio to levels of luciferase
(part B) shown in arbitrary units (AU). All experiments were executed in the absence (white bars) and presence (black bars) of Rev. Error for all
bar graphs is expressed as ±S.D. All experiments were performed in triplicate. D and E. 293T cells were transduced with equivalent amounts of
RT units (6 × 10
5 CPM), as determined for each of the indicated chimeric vectors. The influence of the HIV-1 Rev/RRE system, and 5’ UTR cis
elements, on transduction was assessed by fluorescence microscopy D and FACscan analysis E at 7 days post-transduction. The percent GFP
positive cells are indicated for each FACscan.
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Rev/RRE system was required for cis elements in the 5’
UTR to mediate efficient encapsidation into HIV-1 viral
particles. Furthermore, prior mutagenesis studies have
implicated 5’ UTR cis determinants adjacent to the
canonical packaging signal as important for efficient
RNA encapsidation through loss of function analysis
[5-8]. Our data expand this view by demonstrating that
the 5’ UTR cis elements are not separable to achieve
efficient encapsidation of heterologous RNAs (Figure 3).
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Figure 5 HIV-1 Rev/RRE and cis elements in the 5’ U T Rd on o ta u g m e n tR N Ae n c a p s i d a t i o ni n t oM L Vv i r a lp a r t i c l e s . A.V e c t o rR N A
packaged into MLV derived viral particles was isolated from equivalent amounts of RT units in the media of 293T producer cells. RNA levels
were measured by qRT-PCR and are expressed as arbitrary units (AU). RNA levels are shown in the absence (white bars) and presence (black
bars) of Rev. B. Cytoplasmic RNA was isolated from vector producer cells coincident with harvesting vector particles. Relative levels are expressed
similar to vector RNA in part A. C. Efficiency of encapsidating RNA into MLV viral particles is expressed as a ratio of vector RNA in viral particles
to cytoplasmic RNA available for encapsidation. D. Transduction of 293T cells with MLV/HIV RRE + RU5PS at 5 days post-transduction (no
passaging of cells, P0), and after 5 passages of cells (P5). Percent GFP positive cells were assessed by FACscan analysis and compared to non-
transduced (No Vector) 293T cells. Error for all bar graphs is expressed as ±S.D. All experiments were performed in triplicate.
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role for Rev in RNA encapsidation [17,18,22-24]. Con-
ceivably, the Rev/RRE may impact the cytoplasmic dis-
tribution of RNA without direct involvement in
packaging RNA into viral particles at the plasma mem-
brane, a view consistent with the inability to detect
HIV-1 Rev in viral particles [14]. Additionally, the Rev/
RRE system may alter the conformation of the 5’ UTR
creating a context that is more receptive to an interac-
tion with HIV-1 Gag, and subsequent packaging. Recent
in vitro evidence indicates that HIV-1 Rev can influence
translation in a concentration dependent manner that
does not rely upon the RRE, but rather an interaction
between Rev and a cis determinant in the 5’ UTR [25].
At moderate concentrations Rev enhanced translation,
b u ta th i g hc o n c e n t r a t i o n st r a n s l a t i o nw a si n h i b i t e d
[25]. The same interaction was also implicated in RNA
encapsidation [18], therefore it is plausible that Rev may
promote RNA packaging at high concentrations, possi-
bly acting as a “switch” between translation and encapsi-
dation. Nonetheless, experiments supporting such a
mechanism are still required.
The requirement for the HIV-1 Rev/RRE system in
the encapsidation mechanism implies that the Rev/RRE
may confer specificity onto HIV-1 RNA during the
initial steps of the mechanism when Rev interacts with
RNA in the nucleus. Such a mechanism might ensure
early selection of viral RNA from the milieu of host cell
P0 P0 P5 P5
HIV MLV
NC
2-LTR
1-LTR
Linear
Backbone/
Integrated
D
A B C
Figure 6 Heterologous MLV RNAs form, predominantly, 1-LTR episomal cDNAs following delivery with HIV-1 viral particles.M L V / H I V
RRE + RU5PS chimeric vector was packaged into HIV-1 and MLV viral particles in the presence of Rev. 293T cells were transduced with
equivalent transducing units for HIV-1 and MLV packaged vectors. Total cellular DNA was harvested at 5 days post-transduction (episomal and
integrated vector DNA, P0), and after five cell passages (integrated vector DNA, P5). Vector DNA copy number as measured by qPCR to the
WPRE A, and b-globin DNA copy number B, were determined by qPCR. Data are shown without cell passages (P0; white bars) and after 5 cell
passages (P5; black bars). Vector DNA copy number was normalized to b-globin copy number C, and fold decreases in vector DNA levels, after
passaging cells, are shown. Error for all bar graphs is expressed as ±S.D. D. Southern blot analysis of total DNA isolated from 293T cells
transduced with MLV/HIV RRE + RU5PS vector packaged into either HIV, or MLV, viral particles (as indicated above lanes). Total DNA was isolated
at 5 days posttransduction (P0) and after 5 passages of cells (P5). DNA was digested to distinguish between 2-LTR, 1-LTR, and linear episomal
forms, as well as the vector backbone which is indicative of integrated vector DNA after passaging cells.
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Our data support a role for the Rev/RRE system in con-
ferring specificity of RNA packaged into HIV-1 viral
particles (Figure 3 and 5). The HIV-1 Rev/RRE did not
confer an encapsidation advantage of the heterologous
RNA into MLV viral particles; consistent with the
notion that HIV-1 and MLV utilize distinct mechanisms
to encapsidate viral RNA [26,27]. In the absence of the
HIV-1 Rev/RRE, MLV vector RNA exhibited no added
specificity upon packaging into HIV-1 viral particles, in
agreement with a study showing that a MLV vector
RNA was not enriched in HIV-1 viral particles relative
to cellular mRNAs [28]. Nonspecific (yet measurable)
packaging of MLV RNA raise the concern that stable
A
B
C
MLV Viral Particles HIV Viral Particles
Figure 7 HIV-1 structural and enzymatic proteins can deliver a heterologously packaged RNA to non-dividing cells in vivo. A. MLV/HIV
RRE chimeric vector used to investigate transduction of mouse neurons in vivo following packaging into MLV or HIV-1 viral particles. B. Mouse
brains were injected into the striatum with equivalent transducing units of MLV/HIV RRE vector packaged into either MLV (left panels), or HIV-1
(right panels), derived viral particles. Brain sections were imaged by confocal microscopy following co-staining for neurons (NeuN, red) and
vector particles (GFP, green). Images depicting both vector and neurons can be seen for MLV (top left and low magnification) and HIV (left top
and low magnification) viral particles. Independent images of vector and neurons are shown for MLV (top middle and top right, respectively)
and HIV (left middle and left bottom, respectively) viral particles. C. The graph represents the total number of cells scored for GFP only (white
bars), and colocalized GFP + NeuN (black bars) from 5 mice in each group. Error for bar graph is expressed as ±S.D.
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HIV-1 gag and pol genes with MLV vectors [29,30],
have the potential to package, transfer, reverse tran-
scribe, and recombine HIV-1 gag and pol genes in reci-
pient cells.
Although our system revealed an essential role for the
Rev/RRE system in efficient and specific RNA encapsi-
dation into HIV-1 viral particles, we observed a discre-
pancy between the efficiency of RNA encapsidation
(Figure 3) and p24 normalized titers (Figure 1) for het-
erologous vector RNAs harboring the entire 5’ UTR.
Inclusion of the HIV-1 primer binding site (PBS) and
flanking 5’ UTR sequences might accommodate more
efficient reverse transcription and transduction of the
heterologous RNA, yielding higher titer in the form of
GFP positive cells. Efficient reverse transcription from
the HIV-1 PBS is accomplished by the specific packa-
ging of tRNA
Lys primers into HIV-1 viral particles [20].
Furthermore, the tRNA
Lys primers may also promote
reverse transcription at a low efficiency from the MLV
PBS (normally primed by tRNA
Pro) in the heterologous
MLV vectors that lack a HIV-1 PBS; a rationalization
consistent with a study showing that, although impaired,
HIV-1 replication was retained if the HIV-1 PBS was
altered to that of MLV [31].
The heterologous RNA packaging system yields trans-
duction efficiencies comparable to those of standard
HIV-1 vectors. The unique capacity of the heterologous
vector to remain episomal exposes it to manipulation
for therapeutic gene delivery purposes. Episomal vectors
have recently been sought as safer alternatives to inte-
grating lentiviral vectors for gene therapy protocols
requiring transient gene expression in dividing cells, or
long-term expression in non-dividing cells [32,33]. HIV-
1 delivery of the chimeric heterologous vector resulted
in the dominant formation of 1-LTR episomal forms
(Figure 6), which was indicative of alterations in reverse
transcription. Absence of a HIV-1 3’PPT, 5’PBS, and att
sites may obviate the generation of linear cDNA epi-
somes during reverse transcription, which are precursors
to 2-LTR circles and integration competent linear
cDNA; consistent with a recent report showing that
deletion of the HIV-1 3’ PPT encourages 1-LTR circle
formation at the expense of linear forms [21]. Gene
expression from the chimeric MLV/HIV system remains
a challenge, yet, like non-integrating HIV-1 vectors
[21,34], expression is detectable following in vivo trans-
duction of neurons in the mouse brain striatum (Figure
7). Restricting the synthesis of linear episomes through
t h eu s eo ft h ec h i m e r i cM L V / H I Vv e c t o rs y s t e mm a y
impart improved safety benefits, over conventional non-
integrating HIV-1 vectors, by reducing illegitimate
integration.
Conclusions
Using a heterologous RNA system, we were able to iso-
late the encapsidation and transduction effects of differ-
ent HIV-1 cis and trans components. Most importantly,
however, these studies revealed the concerted effects of
multiple HIV-1 components through gain-of-function
studies. Conventional loss-of-function studies have
implicated several of the aforementioned HIV-1 cis and
trans components in the encapsidation mechanism, but
do not reveal the interdependence of these components.
Our data demonstrate that the HIV-1 Rev/RRE system
is essential for cis elements in the 5’ UTR (including the
canonical packaging signal) to mediate efficient and spe-
cific encapsidation of a heterologous RNA into HIV-1
viral particles. Moreover, the Rev/RRE system could
augment RNA encapsidation independent of all cis ele-
ments from the 5’ UTR. Therefore, we believe that, in
addition to its traditional role in nuclear export, the
Rev/RRE system may have a critical role in making the
HIV-1 RNA more amenable to RNA-RNA and RNA-
protein interactions in the cytoplasm, which support
subsequent RNA encapsidation. Nonetheless, the com-
bined effects of the Rev/RRE system and 5’ UTR cis ele-
ments are not limited to encapsidation since these
components can synergize to yield transduction efficien-
cies that approach those of standard HIV-1 vectors. The
unique transduction properties (1-LTR episomes) asso-
ciated with heterologous RNA, delivered by HIV-1 viral
particles, may prove beneficial for gene therapy proto-
cols. Overall gains in encapsidation and transduction
efficiencies are clearly dependent upon a packaging sys-
tem comprising both the Rev/RRE system and 5’ UTR
cis elements.
Methods
Plasmid Constructs
Murine leukemia virus (MLV) and MLV/HIV chimeric
vector constructs were derived from the MLV vector,
pLNCX [35]. The fundamental MLV vector as described
in Figure 1A was developed as follows: i) the WPRE
(woodchuck hepatitis virus posttranscriptional regulatory
element) was first subcloned into the EcoRI/HindIII sites
of a pCLNCX self-inactivating (SIN) vector [36]; ii)
internal trans elements were replaced with a CMV-GFP
cassette inserted by subcloning a BamHI/XhoI fragment
from pTK113 (HIV-1 vector in Kafri lab), also retaining
the HIV-1 cPPT-CTS (labeled cPPT in Figure 1A) in
this fragment; iii) the 3’ SIN LTR was replaced with a
complete MoMLV 3’ LTR from pLNCX by subcloning
the HindIII/PmeI fragment; and iv) the firefly luciferase
(originally obtained from pBI-GL, Clontech) was sub-
cloned into the BamHI site of the MLV vector generat-
ing pTK1328, the basic MLV vector in Figure 1A. All
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of reference to the plasmid library in the Kafri lab.
All subsequent MLV/HIV chimeric constructs were
derived from pTK1328 by inserting various HIV-1 cis
elements. All HIV-1 cis elements were derived from a
standard HIV-1 vector from our lab, such as pTK113
[37]. The MLV/HIV RRE vector (pTK1332) was derived
from the basic MLV vector by subcloning a BamHI
fragment (~850 bp) comprising the RRE into a BamHI
site of pTK1328. The MLV/HIV RU5PS vector
(pTK1442) was generated by subcloning a BamHI frag-
ment into the BamHI site of pTK1328. The BamHI
fragment was derived from a PCR amplified product ori-
ginally cloned into pCR2.1-TOPO (Invitrogen)
(pTK1428) and moved into the SmaI/Acc65I sites of
pBlueScript (Strategene) (pTK1441). The PCR amplified
product, comprising the HIV-1 R, U5, PBS, and canoni-
cal packaging signal which extends into the 5’ end of
Gag, was generated with the following primers: HIV
RU5 For 5’-gcggccgcttaattaagggtctctctggttagaccagatct-
gagcc-3’; and HIV RU5Pack. Rev 5’-gcggccgcttgctgtgcgg-
3’. The MLV/HIV RRE + RU5 vector (pTK1439) was
constructed by subcloning a PCR amplified fragment
into the NotI site of pTK1332. The PCR amplified pro-
duct was formally cloned into pCR2.1-TOPO (Invitro-
gen) (pTK1427). The following primers were used to
generate a PCR product comprising the HIV-1 R and
U5 regions: HIV RU5 For primer as described above
and HIV RU5 Rev 5’-gcggccgcactgctagagattttccacactgac-
3’. The MLV/HIV RRE + PS vector (pTK1423) was con-
structed by subcloning a fragment, consisting of the
canonical packaging signal and extending into the 5’ end
of Gag and HIV-1 RRE, into the BamHI sites of
pTK1332. Upon cutting with BamHI the existing RRE
in pTK1332 would not be retained. The last construct
in the series, the MLV/HIV RRE + RU5PS vector
(pTK1440), was generated by subcloning the NotI frag-
ment from pTK1428 into the NotI site of pTK1332. The
NotI fragment contains the HIV-1 R, U5, PBS, and
canonical packaging signal extending into the 5’ end of
Gag.
The MLV/HIV RRE vector (pTK1086) described in
Figure 7 was an earlier generation of pTK1332 above,
which did not have the luciferase gene inserted. The
packaging constructs supplying necessary structural/
enzymatic proteins were 4XCTE Gag-Pol (kindly pro-
vided by the laboratory of Dr. Christopher Baum), or
ΔNRF [37]. Expression of structural/enzymatic proteins
from 4X CTE Gag-Pol is independent of all HIV-1
accessory genes, and encodes the complete gag and pol
genes. The HIV-1 Rev protein was independently
e x p r e s s e df r o mt h eE F - 1 a promoter in the E2F-Rev
plasmid. The ΔNRF was described previously, but gag-
pol gene expression is Rev-dependent. The envelope
protein was supplied from pMD.G, a VSV-G expressing
construct.
Cells
293T cells were maintained in DMEM (Hyclone) sup-
plemented with 10% FBS (Invitrogen). Media was also
supplemented with a 100X Antibiotic-Antimycotic solu-
tion containing penicillin, streptomycin, and amphoter-
cin B (Cellgro).
Viral Particle Production and Concentration
Vector particles were produced by transient tranfection
into 293T cells as described previously [38]. Briefly, each
10 cm dish of 293T cells was transfected with 15 μg
vector, 10 μg packaging helper, 5 μgV S V - Ge n v e l o p e ,
and 5 μg Rev expressing plasmids. Plasmid amounts
were compensated for in experiments in the absence of
Rev with the empty plasmid construct, pCI-neo (Pro-
mega). Vector particles were harvested in conditioned
media 48-60 hours post-transfection and filtered
through a 0.45 μm filter. Vector titers were determined
by serial dilution on 293T cells and scoring for GFP
positive cells using a Leica Leitz DMIRB inverted fluor-
escent microscope. Vector titers are expressed as values
normalized to p24 (HIV-1 viral particles), or reverse
transcriptase activity (MLV viral particles). The p24
assay and the reverse transcriptase assays are described
below. Concentration of vector particles was executed as
done previously [38], with the exception that vector was
purified over a single sucrose gradient, concentrated,
and resuspended in 1X PBS.
HIV-1 p24 Capsid Concentration
Details of this assay were described previously [39].
Briefly, EIA/RIA plates were coated with p24 antibody
(NIH AIDS Research and Reference Reagent Program,
#3537) at 1:1000 dilution and incubated overnight at 4°
C. After blocking, samples/standards were treated with a
1% triton x-100 sample buffer, diluted appropriately,
and added to plate for overnight incubation at 4°C.
After washing, polyclonal rabbit anti-p24 antibody (NIH
AIDS Research and Reference Reagent Program,
#SP451T) at 1:300 was added to the plate, and incu-
bated at 37°C for 3 hours. After washing, goat anti-rab-
bit IgG peroxidase (Pierce) at 1:15000 was added to the
plate and incubated at 37°C for 2 hours. Assay was com-
pleted as described previously [39]. Data used for titer
normalization, and determining amount of viral particles
for RNA isolation, are a mean of replicate samples.
MLV Reverse Transcriptase Assay
MLV reverse transcriptase activity was executed on vec-
tor particles (5 μl )h a r v e s t e df r o mt h em e d i ab ym i x i n g
with 25 μl of RT activity reagent (60 mM Tris pH8, 0.6
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6 μg/ml oligo dT16, 25 mM DTT, 0.06% Triton X-100,
and 0.25 mCi/ml
3H-TTP [MP Biomedicals]). After
incubation for 1 hour at 37°C the entire volume was
spotted onto DE81 anion exchange chromatography
paper (Whatman), and placed into 5% Na2PO4 for 5
minutes at room temperature. The samples were washed
at room temperature five times, for 5 minutes each, with
5% Na2PO4 two times with water, and one time with
95% ethanol. The samples were dried, placed in scintilla-
tion fluid, and radioactivity was measured on a Beckman
LS 6500 scintillation counter. Values were recorded as
CPM. Data used for titer normalization, and determin-
ing amount of viral particles for RNA isolation, are a
mean of replicate samples.
FACS Analysis
Details of this assay were described previously [38].
Briefly, at the indicated times post-transduction cells
were fixed, and GFP expression was assessed on a Dako
CyAn flow cytometer at the University of North Caro-
lina Flow Cytometry Core Facility. Data was analyzed
with Summit v4.3.01 software (Dako).
Luciferase Assays
Luciferase lysates were prepared by pelleting transfected
293T cells at the time of vector collection, and resus-
pending the pellet in 1X passive lysis solution (Pro-
mega). After freeze-thawing cell debris was pelleted by
centrifugation for 15 minutes at 14,000 rpm and 4°C.
Equivalent volumes of supernatant were assayed for fire-
fly luciferase expression using 100 μl luciferin reagent
(Promega). Luminescence was measured with a Victor
3
multilabel counter and Wallac 1420 Workstation soft-
ware (Perkin-Elmer). Results are expressed as relative
light units (RLU)/mg protein. Protein concentrations
were assayed according to manufacturer’s instructions
for Pierce BCA Protein Assay kit.
RNA Isolation
At 48-60 hours post-transfection vectors were harvested
from the media, and cells were divided for luciferase
assay, total protein, and cytoplasmic RNA/protein frac-
tionation. Cells were removed from the plate by trypsi-
nizing, and pelleted. The cytoplasmic fraction was
separated by treating the pelleted cells with a MES (2-
(N-morpholino)ethanesulfonic acid) buffered 0.1% Tri-
ton X-100 solution (10 mM MES pH 6.5, 60 mM KCl,
15 mM NaCl, 5 mM MgCl2, 250 mM sucrose, 0.1% Tri-
ton X-100) + protease inhibitor minicocktail (Roche) +
200 units/ml RNase Inhibitor (Fermentas). Pellets were
incubated 2 minutes on ice, and nuclei were pelleted at
1500 rpm and 4°C. The cytoplasmic supernatant fraction
was collected and separated for RNA isolation and
protein analysis. Cytoplasmic fraction was monitored by
western blot analysis for the absence of nucleolin pro-
tein, compared to total cellular proteins. RNA was puri-
fied from the cytoplasmic supernatant using the PARIS
protein and RNA isolation kit (Ambion). Manufacturer’s
instructions were followed starting with addition of the
2X lysis/binding solution to an equal volume of cyto-
plasmic supernatant. Purified RNA was treated with
DNase I Turbo (Ambion) for 1.5 hours at 37°C, and
inactivated according to manufacturer’s instructions.
RNA integrity and concentration were regularly assessed
by agarose gel electrophoresis. Cytoplasmic RNA was
then utilized for analysis in qRT-PCR and northern blot.
Isolation of RNA from vector particles was carefully
executed so that all vectors packaged into HIV-1 viral
particles were normalized for equivalent amounts of p24
prior to isolation. For each sample at the time of RNA
isolation p24 equivalents of vector particles and 5 × 10
6
293T cells were concomitantly added to the RLT lysis
solution in preparation for column purification of the
RNA with the RNeasy Plus Mini kit (Qiagen). Spiking
the vector particles with 293T cells at time of purifica-
tion has multiple advantages: i) 293T cell RNA is a car-
rier during RNA purification; ii) RNA can be easily
quantified after purification; and iii) quantity and integ-
rity of purified RNA can be monitored by agarose gel
electrophoresis. For purposes of homogenization, the
lysed particles/293T cell RNA were passed through a
QIAshredder column (Qiagen) and subsequently
through a genomic DNA eliminator column provided
with the RNeasy plus mini kit. Lysate was then purified
through the RNA isolation column provided with the
RNeasy plus kit. Purified RNA was treated with DNase I
Turbo (Ambion) as described for cytoplasmic RNA.
Vector particle RNA was then utilized for analysis in
qRT-PCR and northern blot. RNA was isolated from
MLV viral particles in a similar fashion, except that viral
particles were normalized for equivalent amounts of
MLV reverse transcriptase. The reverse transcriptase
assay is described above.
qRT-PCR
Purified cytoplasmic and vector RNA were heated to 65°
C for 5 minutes prior to preparing each reverse tran-
scription (RT) reaction. Each RT reaction was prepared
at final concentrations of 1X RT Buffer (Qiagen OmniS-
cript kit), 0.5 mM each dNTP, 10 μMr a n d o mp r i m e
nonamer, 10 units RNase Inhibitor (Fermentas), 500 ng
RNA, and 4 units OmniScript reverse transcriptase (Qia-
gen). As controls for the presence of contaminating
DNA each reaction was also performed in the absence
of reverse transcriptase. Reactions were executed for 1
cycle on a BioRad MyCycler at 37°C for 1 hour. Equiva-
lent amounts of cDNA were used in the subsequent
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pared at final concentrations of 1X ABI Taqman mix
(2X Taqman Gene Expression Master Mix, Applied Bio-
systems), 0.9 μM forward primer, 0.9 μM reverse primer,
and 0.1 μM probe. Reactions were performed at 1 cycle
of 50°C/2 minutes, 1 cycle of 95°C/10 minutes, and 40
cycles of 95°C/15 seconds + 60°C/30 seconds on a 7300
real time PCR system (Applied Biosystems). Vector
RNAs were detected with a primer/probe set to the luci-
ferase gene: For Luc 5’-aggtcttcccgacgatga-3’,R e vL u c5 ’-
gtctttccgtgctccaaaac-3’, and probe #70 (Roche Universal
Probe Library). All quantitative PCR reactions were nor-
malized to an endogenous control reaction for TATA
Binding Protein (TBP) using the following primer/probe
set in independent reactions: For TBP 5’-gaaccacggcact-
gattttc-3’,R e vT B P5 ’-tgccagtctggactgttcttc-3’, and probe
#92 (Roche Universal Probe Library).
The levels of vector RNA (VRNA) and cytoplasmic
RNA (CRNA) derived from the qRT-PCR data are
e x p r e s s e da sa r b i t r a r yu n i t s( A U ) .T h ev a l u e sw e r e
determined by normalizing the cycle threshold (Ct)f o r
luciferase to that obtained for TBP, from each reaction.
The calculation was as follows: 2
-ΔCt,w h e r et h eΔCt is
(Luc Ct -T B PC t). Independent reactions were per-
formed for each VRNA and CRNA sample. All isolated
VRNA could be normalized to TBP since each sample
was copurified with 293T cell RNA, as described above.
Calculation of the encapsidation efficiency, where
VRNA relative to CRNA is expressed as AU, was deter-
mined for each independent sample. The calculation
was as follow: 2
-ΔΔCt, where the ΔΔCt is (VRNA Luc Ct
- VRNA TBP Ct) - (CRNA Luc Ct - CRNA TBP Ct). All
relative encapsidation efficiencies are expressed as an
average of at least three independent experiments with
corresponding standard deviations (S.D.).
Northern Blot Analysis
Cytoplasmic RNA was isolated as described, and vector
RNA was isolated from concentrated vector particles.
Vector RNA was prepared from equivalent levels of p24,
and at the time of isolation the samples were copurified
with 293T cells as described above. Prior to resolving
RNA on a denaturing formaldehyde agarose gel, RNA
was denatured at 65°C for 10 minutes. Equivalent
amounts of cytoplasmic RNA, and vector RNAs, were
resolved on the gel. Northern blot analysis was per-
formed under standard conditions. Probes were random
prime labeled with a
32P-dCTP (Easy Tide Deoxycytidine
5’-triphosphate, Perkin-Elmer) at 37°C for 1 hour.
Probes were either a BstEII fragment from pTK1440
generated to the 5’ end of the vector RNA, or to the
GFP gene located in the 3’ end of the RNA. Images
were obtained on BioMax MR film (Kodak), or by phos-
phorimager (Molecular Dynamics Storm System).
Western Blot Analysis
Cytoplasmic and total cell lysates were resolved by stan-
dard denaturing SDS-PAGE analysis on 10% gels and
blotted to Hybond P membrane. Membranes were
probed with rabbit anti-nucleolin (1 ug/ml; Abcam, cat#
ab22758-100) and rabbit anti-GAPDH (1:500; Santa
Cruz Biotechnology, cat# FL-335). Detection was
achieved by probing blots with goat anti-rabbit IgG per-
oxidase (1:40000; Pierce). All antibody incubations and
washes were done in 1X PBST. Signals were detected
using ECL (GE Healthcare).
Southern Blot Analysis
293T cells were transduced with MLV/HIV RRE +
RU5PS vector packaged into HIV-1 or MLV viral parti-
cles, at a MOI of 5. Total cellular DNA was isolated at
5 days post-transduction (referred to as P0, or no cell
passages, in figures), and after five passages (P5) of the
transduced cells. To collect total DNA transduced cells
were lysed in a proteinase K solution (10 mM Tris pH
8, 10 mM EDTA pH 8, 0.5% SDS, 0.4 M NaCl, and 200
μg/ml proteinase K) for 48 hours at 55°C. Total DNA
was extracted with v/v phenol (Invitrogen) and v/v phe-
nol/chloroform/isoamyl alcohol (Invitrogen) and then
treated with RNase A (20 μg; Fermentas) at 37°C for 2
hours. A second round of extractions was performed
and total DNA was precipitated using standard ethanol
precipitation.
Isolated gDNA (10 μg) was digested with BsrGI and
DpnI for ~24 hours at 37°C. DpnI was included to elim-
inate putative plasmid DNA carry-over from the trans-
fections during vector production in 293T cells.
Equivalent amounts of gDNA were resolved on 1% agar-
ose gels, transferred to Zetaprobe membrane, and
probed with a BstEII fragment from pTK1440 that
recognizes the 5’ end of the vector enabling a size dis-
tinction between linear, 1-LTR, 2-LTR and backbone/
integrated forms. Images were captured on BioMax MR
Film (Kodak), or by phosphorimager (Molecular
Dynamics Storm System).
Real Time qPCR
Total cellular DNA was isolated as described for South-
ern blot analysis and qPCR for vector and b-globin were
described previously [39]. Briefly, vector copy number
was derived from standard curve produced from FLP9
cells, which contain a single copy of HIV-1 vector per
diploid genome. One nanogram of total cellular DNA
was previously calculated to contain 303 copies for b-
globin per diploid genome, or 151.5 copies vector per
diploid genome. Primers for vector copy number were
designed to the WPRE region, which is also in our
MLV/HIV chimeric vectors. All primers and PCR reac-
tion conditions were described previously [39].
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Female C57Bl/6 mice (n = 10), 3 months old (Jackson
Labs) were housed in standard conditions with 3-4 mice
per cage with food and water available ad libitum.A l l
procedures were in accordance with the Guide for the
Care and Use of Laboratory Animals (DHHS Publication
No. (National Institutes of Health) 85-23), and all proce-
dures received prior approval by the NIH Institutional
Animal Care and Usage Committee. All procedures
were performed according to animal protocol number,
396-LNS-2014.
Stereotaxic Administration of Retroviral Vectors
Mice were anesthetized (Avertin 0.02 mg/ml, 0.5-1.0 ml
injection per mouse), and MLV retrovirus (n = 5 mice),
or HIV lentivirus (n = 5 mice) was injected stereotacti-
cally (2 μlu s i n ga5μl Hamilton microliter syringe) into
the right striatum (AP = 1.0 mm anterior from bregma;
lateral = 1.5 mm; ventral = 3.0 mm). Studies were exe-
cuted with the MLV/HIV RRE vector (Figure 7A) pack-
aged into MLV viral particles, or HIV-1 viral particles
generated from the ΔNRF [37] helper construct. One
month thereafter animals were given an overdose of
anesthetics and perfused transcardially with cold 4%
paraformaldehyde (PFA) in 0.1 M phosphate buffered
saline (PBS). After 24 hr, brain tissue was equilibrated
in 30% sucrose. Sequential horizontal sections (40 μm)
using a sliding freezing microtome (HM450, Thermo-
Fisher) were taken through the extent of the striatum
and stored in phosphate buffered glycerol at -20°C.
Immunohistochemistry and Confocal Microscopy
Double labeling for the neuronal marker NeuN and GFP
was done on a 1:6 series of 40-μm free-floating horizontal
sections as described previously [40]. Sections were
washed and blocked in TBS with 3% donkey serum and
0.3% Triton X-100 (TBS-plus). Primary antibodies raised
in two different species were pooled in TBS-plus and
i n c u b a t e df o r4 8ha t4 ° C .T h en e u r o n a lm a r k e rN e u N
[mouse monoclonal antibody, (Millipore) 1:100] was
combined with antibody for GFP [rabbit polyclonal anti-
body (Millipore), 1:1000]. Corresponding secondary anti-
bodies [donkey anti-mouse CY3 and goat anti-rabbit
Alexa488 (Jackson ImmunoResearch Inc.), 1:250] were
pooled, and sections were incubated for 4 h at room tem-
perature following washing in TBS-plus. Sections were
mounted and coverslipped with DABCO-PVA. Sections
were imaged by confocal scanning laser microscopy
(MPE1000, Olympus and Laser Scanning Zeiss 510
Meta). Brain sections with GFP positive cells were cap-
tured with the Zeiss LSM Image Browser software and
used to score for GFP, NeuN, and colocalization of the
two markers by scanning through the z-axis. Scoring
represents positive cells from brain sections of mice
transduced with the MLV/HIV RRE vector packaged into
MLV (n = 5), or HIV-1 (n = 5), derived viral particles.
Additional material
Additional file 1: Figure S1. Cytoplasmic separation and transfection
assessment. A. At the time of harvesting vectors total and cytoplasmic
protein fractions were routinely collected from the producer 293T cells to
monitor separation of the cytoplasmic fraction. Equivalent amounts of
total (TP) and cytoplasmic (CP) protein lysates were analyzed for
nucleolin (a nuclear specific protein), and GAPDH, by western blot
analysis. Three independent experiments are shown for the MLV/HIV RRE
+ RU5PS vector packaged into HIV-1 particles in the presence of Rev. B.
Cytoplasmic RNAs isolated from transfected producer 293T cells at the
time of vector harvest. Four independent experiments (lanes 1-4) were
analyzed by denaturing northern blot analysis. The MLV/HIV RRE + RU5PS
vector RNA is shown in the absence of Rev (two separate experiments;
lanes 1 and 2) and in the presence of Rev (two separate experiments;
lanes 3 and 4). Dilutions of vector RNA in lane 4 were also resolved at
50% (lane 5), and 20% (lane 6). Actin was probed as a positive control.
The band densities were quantitated by phosphorimager for vector (C)
and actin (D). Numbers below each bar correlate with lanes on northern
blots.
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